Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269537 | 0.74 | GBA1 (0.42) | GBA1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22722 | 0.74 | GBA1 (0.42) | GBA1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL56215 | 0.72 | TAAR1 (0.41) | GBA1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL448797 | 0.71 | ALDH1A1 (0.41) | GBA1 | |
| SCHEMBL25585 | 0.71 | ALDH1A1 (0.41) | GBA1 | |
| SCHEMBL6432088 | 0.71 | SLC6A2 (0.44) | GBA1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1491164 | 0.69 | ALDH1A1 (0.40) | GBA1 | |
| SCHEMBL3950950 | 0.69 | ALDH1A1 (0.40) | GBA1 | |
| SCHEMBL29910925 | 0.69 | NPC1 (0.55) | GBA1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL989433 | 0.69 | SLC6A2 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | claimed |
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | claimed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | claimed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | claimed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | claimed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| EP-2970258-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| EP-1603879-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | claimed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | claimed |
| WO-2004078128-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | claimed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | claimed |
| EP-0536169-B1 | [3H,7H]THIAZOLO [3,4-a]PYRIDINES WITH ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIONS ON THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA (IT) | 1995-04-05 | — | — | EP | claimed |
| US-5336676-A | [3H,7H]thiazolo[3,4-a]pyridines with antiasthmatic and antiinflammatory actions on the respiratory tract | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1994-08-09 | — | — | US | claimed |
| WO-1993011134-A1 | [3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-06-10 | — | — | WO | claimed |
| US-4006244-A | INSECTICIDE, FUNGICIDE, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | GBA1 578/4885TAAR1 395/4885SLC6A2 1970/4885 |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | GBA1 969/4885TAAR1 802/4885SLC6A2 387/4885 |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | CDK4, MKI67, TP53 | GBA1 2452/4885TAAR1 3758/4885SLC6A2 4205/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | GBA1 3537/4885TAAR1 3629/4885SLC6A2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.